Výsledky vyhledávání - M. E. Scheulen

  • Zobrazuji výsledky 1 - 14 z 14
Upřesnit hledání
  1. 1
    Ultradeep sequencing detects <scp><i>GNAQ</i></scp> and <scp><i>GNA11</i></scp> mutations in cell‐free <scp>DNA</scp> from plasma of patients with uveal melanoma

    Ultradeep sequencing detects <scp><i>GNAQ</i></scp> and <scp><i>GNA11</i></scp> mutations in cell‐free <scp>DNA</scp> from plasma of patients with uveal melanoma Autor Claudia H.D. Metz, M. E. Scheulen, Norbert Bornfeld, Dietmar Lohmann, Michael Zeschnigk

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery

    Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery Autor V. Sadony, Michael Körber, Guido Albes, Volker Podtschaske, Thorleif Etgen, Thomas Trösken, Ursula Ravens, M. E. Scheulen

    Vydáno 1998
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  3. 3
    First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors Autor K. Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Angelika C. Stern, Hendrik Gille, Laurent Audoly, M. E. Scheulen

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Risk factors for venous thromboembolic events in cancer patients

    Risk factors for venous thromboembolic events in cancer patients Autor Knut Kröger, Dorothea Weiland, Claudia Ose, Niklas Neumann, Steven J. Weiss, Calvin H. Hirsch, Krzysztof Urbański, S. Seeber, M. E. Scheulen

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

    Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study Autor Dirk Strumberg, M. E. Scheulen, Beate Schultheis, Heike Richly, Annette Frost, Martin Büchert, O. Christensen, Michael Jeffers, Roland Heinig, Oliver Boix, K. Mross

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

    A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central... Autor K. Mross, Christian Dittrich, Walter E. Aulitzky, Dirk Strumberg, J. Schütte, Roland M. Schmid, S. Hollerbach, Michael Merger, Gerd Munzert, Frank Fleischer, M. E. Scheulen

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

    A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research... Autor Simone Steinbild, K. Mross, Annette Frost, R. Morant, Silke Gillessen, C. Dittrich, Dirk Strumberg, Andreas Hochhaus, A.-R. Hanauske, Lutz Edler, Iris Burkholder, M. E. Scheulen

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

    Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors Autor Sebastian Bauer, R A Hilger, Thomas Mühlenberg, Florian Grabellus, James Nagarajah, Mathias Hoiczyk, Annette Reichardt, Marit Ahrens, Peter Reichardt, Susanne Grünewald, M. E. Scheulen, A. Pustowka, E Bock, Martin Schüler, Daniel Pink

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

    Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid... Autor Dirk Strumberg, Heike Richly, Ralf A. Hilger, N. Schleucher, Sönke Korfee, Mitra Tewes, Markus Faghih, E. Brendel, D. Voliotis, Claus G. Haase, Brian Schwartz, Ahmad Awada, R. Voigtmann, M. E. Scheulen, S. Seeber

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

    Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors Autor Heike Richly, Bernhard F. Henning, P. Kupsch, K. Passarge, M. Grubert, Ralf A. Hilger, O. Christensen, E. Brendel, Brian Schwartz, Matthias Ludwig, C. Flashar, R. Voigtmann, M. E. Scheulen, S. Seeber, Dirk Strumberg

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

    Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased r... Autor Dietrich W. Beelen, Rudolf Trenschel, J. Casper, Mathias Freund, Ralf A. Hilger, M. E. Scheulen, Nadežda Basara, A. A. Fauser, Bernd Hertenstein, H. A. Mylius, Joachim Baumgart, Uwe Pichlmeier, J. Hahn, Ernst Holler

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

    Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial Autor Serge Leyvraz, Sophie Piperno‐Neumann, Stefan Suciu, J.F. Baurain, Marcin Zdzienicki, Alessandro Testori, Ernest Marshall, M. E. Scheulen, Thomas Jouary, Sylvie Négrier, Jan B. Vermorken, Eckhart Kaempgen, Xavier Durando, Dirk Schadendorf, Ravichandra Karra Gurunath, Ulrich Keilholz

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

    Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors Autor Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Avinash Gupta, Vanesa López-Valverde, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, Steve Blotner, Valérie Meresse Naegelen, Jan H.M. Schellens, Wilfried Eberhardt

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

    Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer Autor Stephen Chan, M. E. Scheulen, S. Johnston, K. Mross, Fátima Cardoso, Christian Dittrich, W. Eiermann, Dagmar Hess, Rudolph Morant, Semiglazov Vf, Markus Borner, Marc Salzberg, Valerijus Ostapenko, H. J. Illiger, Dirk Behringer, Nathalie Bardy‐Bouxin, Joseph Boni, Steven Kong, Maria Cincotta, Laurence Moore

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: